NeoImmuneTech Receives Italy Approval for NT-I7 Phase 2 Clinical Trial in Stomach and Esophageal Cancer
[Asia Economy Reporter Minji Lee] NeoImmuneTech (Reg.S) announced on the 7th that it has received approval in Italy for a Phase 2 clinical trial plan involving the combination therapy of NT-I7 and Nivolumab, as well as Nivolumab monotherapy, targeting subjects with advanced or metastatic gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal cancer.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "The purpose is to evaluate the therapeutic safety, tolerability, and efficacy of the combination therapy of NT-I7 and Nivolumab."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
